

| Health Outcomes | Short-term Studies | | | Long-term Studies | | |
|--|--------------------|-------------------|-----|-------------------|-------------------|-----|
| | PM ₁₀ | PM _{2.5} | UFP | PM ₁₀ | PM _{2.5} | UFP |
| Mortality | | | | | | |
| All causes | XXX | XXX | X | XX | XX | X |
| Cardiovascular | XXX | XXX | X | XX | XX | X |
| Pulmonary | XXX | XXX | X | XX | XX | X |
| Pulmonary effects | | | | | | |
| Lung function, eg, PEF | XXX | XXX | XX | XXX | XXX | |
| Lung function growth | | | | XXX | XXX | |
| Asthma and COPD exacerbation | | | | | | |
| Acute respiratory symptoms | | XX | X | XXX | XXX | |
| Medication use | | | X | | | |
| Hospital admission | XX | XXX | X | | | |
| Lung cancer | | | | | | |
| Cohort | | | | XX | XX | X |
| Hospital admission | | | | XX | XX | X |
| Cardiovascular effects | | | | | | |
| Hospital admission | XXX | XXX | | X | X | |
| ECG-related endpoints | | | | | | |
| Autonomic nervous system | XXX | XXX | XX | | | |
| Myocardial substrate and vulnerability | | XX | X | | | |
| Vascular function | | | | | | |
| Blood pressure | XX | XXX | X | | | |
| Endothelial function | X | XX | X | | | |
| Blood markers | | | | | | |
| Pro-inflammatory mediators | XX | XX | XX | | | |
| Coagulation blood markers | XX | XX | XX | | | |
| Diabetes | X | XX | X | | | |
| Endothelial function | X | X | XX | | | |
| Reproduction | | | | | | |
| Premature birth | X | X | | | | |
| Birth weight | XX | X | | | | |
| IUR/SGA | X | X | | | | |
| Fetal growth | | | | | | |
| Birth defects | X | | | | | |
| Infant mortality | XX | X | | | | |
| Sperm quality | X | X | | | | |
| Neurotoxic effects | | | | | | |
| Central nervous system | | X | XX | | | |

Notes: X, few studies. XX, many studies. XXX, large number of studies.
Abbreviations: UFP, ultrafine particle; PEF, peak expiratory flow; COPD, chronic obstructive pulmonary disease; IUG, intrauterine growth restriction; SGA, small for gestational age.